Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash & Equivalents: 2023-2024

Historic Cash & Equivalents for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $21.9 million.

  • Contineum Therapeutics' Cash & Equivalents rose 4.26% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 4.26%. This contributed to the annual value of $21.9 million for FY2024, which is 41.33% up from last year.
  • As of FY2024, Contineum Therapeutics' Cash & Equivalents stood at $21.9 million, which was up 41.33% from $15.5 million recorded in FY2023.
  • Over the past 5 years, Contineum Therapeutics' Cash & Equivalents peaked at $21.9 million during FY2024, and registered a low of $15.5 million during FY2023.
  • Over the past 2 years, Contineum Therapeutics' median Cash & Equivalents value was $18.7 million (recorded in 2023), while the average stood at $18.7 million.
  • Data for Contineum Therapeutics' Cash & Equivalents shows a peak YoY skyrocketed of 41.33% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Cash & Equivalents stood at $15.5 million in 2023, then surged by 41.33% to $21.9 million in 2024.